van Wijck Albert J M, Opstelten Wim, Moons Karel G M, van Essen Gerrit A, Stolker Robert J, Kalkman Cornelis J, Verheij Theo J M
Pain Clinic, Department of Anaesthesiology, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, Netherlands.
Lancet. 2006 Jan 21;367(9506):219-24. doi: 10.1016/S0140-6736(06)68032-X.
Postherpetic neuralgia is the most frequent complication of herpes zoster. Treatment of this neuropathic pain syndrome is difficult and often disappointing. We assessed the effectiveness of a single epidural injection of steroids and local anaesthetics for prevention of postherpetic neuralgia in older patients with herpes zoster.
We randomly assigned 598 patients older than 50 years, with acute herpes zoster (rash <7 days) below dermatome C6, to receive either standard therapy (oral antivirals and analgesics) or standard therapy with one additional epidural injection of 80 mg methylprednisolone acetate and 10 mg bupivacaine. The primary endpoint was the proportion of patients with zoster-associated pain 1 month after inclusion. Analyses were by intention-to-treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN32866390.
At 1 month, 137 (48%) patients in the epidural group reported pain compared with 164 (58%) in the control group (relative risk [RR] 0.83, 95% CI 0.71-0.97, p=0.02). After 3 months these values were 58 (21%) and 63 (24%) respectively (0.89, 0.65-1.21, p=0.47) and, at 6 months, 39 (15%) and 44 (17%; 0.85, 0.57-1.13, p=0.43). We detected no subgroups in which the relative risk for pain 1 month after inclusion substantially differed from the overall estimate. No patient had major adverse events related to epidural injection.
A single epidural injection of steroids and local anaesthetics in the acute phase of herpes zoster has a modest effect in reducing zoster-associated pain for 1 month. This treatment is not effective for prevention of long-term postherpetic neuralgia.
带状疱疹后神经痛是带状疱疹最常见的并发症。这种神经性疼痛综合征的治疗困难且常常令人失望。我们评估了单次硬膜外注射类固醇和局部麻醉剂对老年带状疱疹患者预防带状疱疹后神经痛的有效性。
我们将598例年龄大于50岁、急性带状疱疹(皮疹出现时间<7天)且病变位于胸6皮节以下的患者随机分为两组,一组接受标准治疗(口服抗病毒药物和镇痛药),另一组在标准治疗基础上额外接受一次硬膜外注射80mg醋酸甲泼尼龙和10mg布比卡因。主要终点是纳入研究后1个月时伴有带状疱疹相关疼痛的患者比例。分析采用意向性分析。本研究已注册为国际标准随机对照试验,编号为ISRCTN32866390。
1个月时,硬膜外注射组有137例(48%)患者报告有疼痛,而对照组有164例(58%)(相对危险度[RR]0.83,95%可信区间0.71 - 0.97,p = 0.02)。3个月时,相应数值分别为58例(21%)和63例(24%)(RR 0.89,95%可信区间0.65 - 1.21,p = 0.47),6个月时,分别为39例(15%)和44例(17%;RR 0.85,95%可信区间0.57 - 1.13,p = 0.43)。我们未发现纳入研究后1个月时疼痛相对危险度与总体估计值有显著差异的亚组。没有患者出现与硬膜外注射相关的严重不良事件。
在带状疱疹急性期单次硬膜外注射类固醇和局部麻醉剂对减轻带状疱疹相关疼痛有适度效果,持续1个月。这种治疗方法对预防长期带状疱疹后神经痛无效。